Incidence of silent cerebral lesions during pulsed field ablation for paroxysmal atrial fibrillation.

Ann MedMar 3, 2026 (epub)
Clinical ResearchCardiologyOpen access

Peiqi Ding, Wensu Chen, Jianfan Shen et al.

✦ AI-curated · Sources linked

In 30 seconds

This prospective pilot randomised controlled trial compared silent cerebral lesions (SCLs) after pulsed field ablation (PFA) versus radiofrequency catheter ablation (RFCA) in 62 patients with paroxysmal atrial fibrillation. Brain MRI was performed before and 24–48 hours after ablation. New lesions without neurological deficits were found in 12.90% (4/31) of the PFA group and 6.45% (2/31) of the RFCA group; the difference was not statistically significant (p = 0.67). Univariate analyses also linked several cardiac dimensions and procedural times with SCL status.

Key findings

  • Post-procedure SCLs occurred in 12.90% (4/31) after PFA and 6.45% (2/31) after RFCA.
  • The between-group difference in SCL incidence was not statistically significant (p = 0.67).
  • Left atrium dimension, left atrial operation time, left ventricular end-diastolic dimension, and total operation time were higher in the SCL group in univariate analyses.

Why it matters

MRI-detected cerebral lesions are a potential complication of atrial fibrillation ablation, even without neurological deficits. This small randomised comparison provides perioperative imaging data for both techniques, but its results do not establish a difference in cerebral safety. The numerical imbalance and exploratory associations with procedural measures identify questions for further evaluation.

What to keep in mind

This was a pilot trial with 62 patients and only six detected SCLs, limiting the ability to identify between-group differences or establish risk factors.

Source

Published in Ann Med. This summary was written by xxcode from the publication's abstract and metadata. It is not peer reviewed and is not a substitute for the original article. For clinical decisions, review the original publication.

ShareTelegramLinkedIn

AI-generated summaries may contain errors or omissions. Verify clinically important information with the original publication.

More in Cardiology

Clinical ResearchOncology (Medical)

Zamtocabtagene autoleucel, a tandem CD20-CD19-directed CAR T-cell therapy, for second line treatment of large B-cell lymphoma in patients ineligible for transplantation (DALY 2-EU): primary analysis of an open-label, multicentre, randomised phase 2 study.

DALY 2-EU was an open-label, multicentre, randomised phase 2 trial comparing tandem CD20-CD19-directed zamtocabtagene autoleucel (zamto-cel) with R-GemOx in adults with second-line relapsed or refractory large B-cell…

Lancet OncolOct 27, 2026Read summary
Clinical ResearchOncology (Medical)

Neoadjuvant short-course radiotherapy followed by camrelizumab and chemotherapy versus standard of care for locally advanced rectal cancer (UNION): a prespecified interim analysis of a multicentre, open-label, randomised, phase 3 trial.

UNION was a multicentre, open-label, randomised phase 3 trial at nine hospitals in China comparing neoadjuvant short-course radiotherapy followed by camrelizumab plus CAPOX with long-course chemoradiotherapy followed by…

Lancet OncolOct 25, 2026Read summary
Clinical ResearchHematology

Efficacy and safety of mitapivat in patients with sickle cell disease (RISE UP): a phase 3, double-blind, global, randomised, placebo-controlled trial.

RISE UP was a phase 3, double-blind, global, randomised, placebo-controlled trial conducted at 69 sites in 15 countries. It evaluated twice-daily mitapivat in patients older than 16 years with sickle cell disease…

LancetOct 24, 2026Read summary

Want this personalized?

Stop searching the literature. Choose what you follow and xxcode will build your personalized medical digest.

  • Your specialties
  • Your filters and thresholds
  • Clinical Research + Case Reports, tuned separately
  • Automatic weekly delivery
  • Audio and text

Prefer listening? Personalized audio digests are available with Pro.

Stay updated for free

Get the 3 most interesting publications in one specialty each week.

Weekly email. Unsubscribe anytime.